You are here
P&T May 2015
Sessions on antibiotics at a pharmacists’ convention help put a 14-year-old case of strep throat in perspective, showing what has changed, what hasn’t, and what should. But there’s hope on the horizon (for antibiotics and for those gowns, too).
Washington politicians appear to agree on the need for a vigorous effort to develop genetic tests and targeted, genomic medicines that reach small populations within specific disease groups. Still, the quest for “precision medicine” has some skeptics.
Controlling antibiotic-resistant bacteria calls for widespread adoption of antibiotic stewardship programs; better diagnosis, tracking and prescribing practices; optimized therapeutic regimens; prevention of infection transmission—and new drugs.
A study shows customized order-entry sets for antiretroviral therapy to manage human immunodeficiency virus reduced the potential for prescribing incorrect regimens and may be useful when HIV-specific medication reconciliation is unavailable.
Topics included a new agent to lower cholesterol and the use of cangrelor, bivalirudin, unfractionated heparin, ticagrelor, and Bendavia for acute coronary syndromes.
As researchers seek more-effective, safer medications to treat human immunodeficiency virus, the focus has shifted to fixed-dose, single-tablet combinations.
Seeking proof of P&T committee members’ independence
Bulk packages of IV contrast media used inappropriately
FDA approvals, drug indications, and updates
Filgrastim-sndz (Zarxio) to help prevent infections related to chemotherapy, dinutuximab (Unituxin) for high-risk pediatric neuroblastoma, and panobinostat (Farydak) for multiple myeloma